Abstract

Long Term Objective: To make commercially available central venous catheters (CVC) which have been chemically treated to reduce their tendency to induce infections thereby bringing major humanitarian benefits and substantial reductions in hospital care costs.
Specific Aims and Methodology: (1) apply an already developed process for antimicrobial protection of silicone rubber to a commonly used CVC (Hickman) device; (2) determine the duration and levels of antimicrobial activity of optimally treated catheters during perfusion with saline, nutritional, and oncotherapeutic solutions; (3) determine the degrees of protection of treated catheters against lumen colonization in vitro, by methods used in (2) above; (4) determine the biocompatibility in mouse tissue of the treated catheter material; (5) determine the effects of normal storage on antibacterial activity and tensile strength of treated catheters.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL037164-01A1
Application #
3500953
Study Section
(SSS)
Project Start
1987-08-01
Project End
1988-04-14
Budget Start
1987-08-01
Budget End
1988-04-14
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
Denver Biomaterials, Inc.
Department
Type
DUNS #
City
Evergreen
State
CO
Country
United States
Zip Code
80439

  Publications

Hippen, K L; O'Connor, R S; Lemire, A M et al. (2017) In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. Am J Transplant 17:3098-3113
Szady, Anita D; Pepine, Carl J; Sharma, Shreela V et al. (2013) A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials. Curr Atheroscler Rep 15:341
Richman, Sara; Gee, Adrian P; McKenna, David H et al. (2012) Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network Transfusion 52:2225-33
Traverse, Jay H; Henry, Timothy D; Ellis, Stephen G et al. (2011) Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 306:2110-9
Hippen, Keli L; Merkel, Sarah C; Schirm, Dawn K et al. (2011) Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 3:83ra41
Hippen, K L; Merkel, S C; Schirm, D K et al. (2011) Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant 11:1148-57
Matthay, Michael A; Thompson, B Taylor; Read, Elizabeth J et al. (2010) Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 138:965-72
McKenna Jr, David H; Adams, Sheryl; Sumstad, Darin et al. (2010) CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine. Cytotherapy 12:170-7
Traverse, Jay H; Henry, Timothy D; Vaughan, Douglas E et al. (2010) LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J 37:412-20
Gee, Adrian P; Richman, Sara; Durett, April et al. (2010) Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy 12:684-91

Showing the most recent 10 out of 12 publications